Cue Biopharma, Inc. (CUE)
NASDAQ: CUE · Real-Time Price · USD
0.2069
-0.0230 (-10.00%)
Apr 1, 2026, 11:12 AM EDT - Market open
Cue Biopharma Revenue
In the year 2025, Cue Biopharma had annual revenue of $27.47M with 195.75% growth. Cue Biopharma had revenue of $21.94M in the quarter ending December 31, 2025, with 1,292.26% growth.
Revenue (ttm)
$27.47M
Revenue Growth
+195.75%
P/S Ratio
0.82
Revenue / Employee
$947,103
Employees
29
Market Cap
20.21M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 27.47M | 18.18M | 195.75% |
| Dec 31, 2024 | 9.29M | 3.80M | 69.16% |
| Dec 31, 2023 | 5.49M | 4.25M | 340.96% |
| Dec 31, 2022 | 1.25M | -13.70M | -91.67% |
| Dec 31, 2021 | 14.94M | 11.79M | 373.68% |
| Dec 31, 2020 | 3.15M | -304.01K | -8.79% |
| Dec 31, 2019 | 3.46M | 2.32M | 202.67% |
| Dec 31, 2018 | 1.14M | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Neuphoria Therapeutics | 14.99M |
| Barinthus Biotherapeutics | 14.97M |
| Curis | 9.44M |
| Marker Therapeutics | 3.55M |
| ABVC BioPharma | 797.92K |
| Vistagen Therapeutics | 789.00K |
| Outlook Therapeutics | 205.70K |
| Serina Therapeutics | 130.00K |
CUE News
- 4 days ago - Cue Biopharma Announces CEO Transition - GlobeNewsWire
- 6 days ago - Cue Biopharma to Host Virtual R&D Day Event on April 7, 2026 - GlobeNewsWire
- 15 days ago - Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - GlobeNewsWire
- 23 days ago - Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026 - GlobeNewsWire
- 6 weeks ago - Cue Biopharma Announces Preclinical Safety and Tolerability Data for CUE-401 for the Treatment of Autoimmune and Inflammatory Diseases - GlobeNewsWire
- 6 weeks ago - Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business Officer - GlobeNewsWire
- 3 months ago - Cue Biopharma Announces Pricing of $10 Million Public Offering - GlobeNewsWire
- 3 months ago - Cue Biopharma Announces Proposed Public Offering - GlobeNewsWire